Proto Script Pharmaceutical (PSCR) Stock Price

Proto Script Pharmaceutical Price

NYSE·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

The stock trades about 100% above its 52-week low.

Proto Script Pharmaceutical stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Proto Script Pharmaceutical over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Proto Script Pharmaceutical stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Proto Script Pharmaceutical's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Proto Script Pharmaceutical Stock Price History
DateProto Script Pharmaceutical Price
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/3/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/19/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
1/29/20260.00 USD
1/5/20260.00 USD
12/9/20250.00 USD
10/21/20250.00 USD
10/17/20250.00 USD
10/15/20250.00 USD
10/2/20250.00 USD
9/22/20250.00 USD
9/15/20250.00 USD
8/27/20250.00 USD
8/1/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Proto Script Pharmaceutical Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2010
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2011
0.00 USD
-32,900.00 USD
-32,900.00 USD
Jan 1, 2012
0.00 USD
-32,400.00 USD
-32,400.00 USD
Jan 1, 2013
0.00 USD
-38,300.00 USD
-38,300.00 USD
Jan 1, 2014
0.00 USD
-45,200.00 USD
-45,200.00 USD
Jan 1, 2015
0.00 USD
-33,100.00 USD
-33,100.00 USD
Jan 1, 2016
789,000.00 USD
-298,100.00 USD
-7.18 M USD

Proto Script Pharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 17, 2026, 3:29 AM
 
NET INCOMEM USD
SHARESM
2010201120122013201420152016
––––––-7.00
40.0028.2930.2730.4830.4830.48316.30
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Proto Script Pharmaceutical generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Proto Script Pharmaceutical retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Proto Script Pharmaceutical's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Proto Script Pharmaceutical has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Proto Script Pharmaceutical's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Proto Script Pharmaceutical stock margins

The Proto Script Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Proto Script Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Proto Script Pharmaceutical.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2010
71.55 %
0.00 %
0.00 %
Jan 1, 2011
71.55 %
- %
- %
Jan 1, 2012
71.55 %
- %
- %
Jan 1, 2013
71.55 %
- %
- %
Jan 1, 2014
71.55 %
- %
- %
Jan 1, 2015
71.55 %
- %
- %
Jan 1, 2016
71.55 %
-37.78 %
-910.35 %

Proto Script Pharmaceutical Stock Revenue, EBIT, Earnings per Share

The Proto Script Pharmaceutical earnings per share therefore indicates how much revenue Proto Script Pharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2010
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2011
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2012
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2013
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2014
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2015
0.00 USD
-0.00 USD
-0.00 USD
Jan 1, 2016
0.00 USD
-0.00 USD
-0.02 USD

Proto Script Pharmaceutical business model & stock analysis

Proto Script Pharmaceutical Corp is an American biotechnology company specializing in the development and manufacture of innovative, high-quality drugs. The company is focused on researching new breakthrough technologies in drug manufacturing to find potential cures and treat diseases. Their business model is based on producing medications that are highly effective and of high quality while also being cost-effective and patient-friendly. They collaborate closely with biotechnology companies and academic institutions to acquire the best technologies and develop effective and innovative drugs. They have products in the areas of neurology, endocrine health, and oncology. They have also entered into partnerships with other companies to expand and further develop their products. Overall, Proto Script Pharmaceutical Corp is a groundbreaking company in the biotechnology field with decades of experience in drug development and a commitment to improving the lives of millions of people worldwide.

Proto Script Pharmaceutical SWOT Analysis

Strengths

Proto Script Pharmaceutical Corp has a strong and experienced management team, who possess extensive knowledge and expertise in the pharmaceutical industry. This enables the company to make informed decisions and effectively navigate the complex landscape.

The company has a robust research and development (R&D) department, which continually explores new drug formulations and technologies. This allows Proto Script Pharmaceutical Corp to stay innovative and maintain a competitive edge in the market.

Proto Script Pharmaceutical Corp has established a strong brand reputation for delivering high-quality pharmaceutical products. The company's commitment to maintaining rigorous quality control standards has gained the trust and loyalty of healthcare professionals and patients alike.

Weaknesses

One weakness of Proto Script Pharmaceutical Corp is its heavy reliance on a limited number of key products. This concentration of revenue poses a risk, as any adverse events or market changes affecting those products could have a significant negative impact on the company's financial performance.

The company may face challenges in securing regulatory approvals for new drug candidates, leading to potential delays in product launches and revenue generation. This could hinder Proto Script Pharmaceutical Corp's ability to expand its product portfolio and compete effectively.

Proto Script Pharmaceutical Corp might also lack a diversified customer base in certain geographical regions. This dependency on a few markets increases vulnerability to changes in local regulations, economic conditions, and geopolitical factors.

Opportunities

The increasing global demand for pharmaceutical products presents a significant growth opportunity for Proto Script Pharmaceutical Corp. The company can leverage its R&D capabilities to develop new drugs and expand its market reach, especially in emerging markets.

Proto Script Pharmaceutical Corp can explore strategic partnerships or acquisitions to broaden its product portfolio and gain access to new technologies. Such collaborations can enhance the company's competitiveness and drive revenue growth.

The growing importance of personalized medicine and advancements in genetic research provide an opportunity for Proto Script Pharmaceutical Corp to develop targeted therapies that cater to specific patient populations. This could result in improved treatment outcomes and considerable market differentiation.

Threats

Proto Script Pharmaceutical Corp faces intense competition from both established pharmaceutical companies and emerging biotech startups. This competitive landscape poses a threat to the company's market share and profitability.

Changes in healthcare policies, regulations, or pricing structures could impact the pricing and reimbursement of pharmaceutical products. This can lead to pricing pressures and reduced profitability for Proto Script Pharmaceutical Corp.

The emergence of counterfeit drugs and intellectual property infringements poses a threat to Proto Script Pharmaceutical Corp's brand reputation and revenue. The company needs to invest in robust anti-counterfeit measures and proactive intellectual property protection strategies.

Proto Script Pharmaceutical Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Proto Script Pharmaceutical historical P/E ratio, EBIT multiple, and P/S ratio

Proto Script Pharmaceutical annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Proto Script Pharmaceutical shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2010
40.00 M Stocks
Jan 1, 2011
28.29 M Stocks
Jan 1, 2012
30.27 M Stocks
Jan 1, 2013
30.48 M Stocks
Jan 1, 2014
30.48 M Stocks
Jan 1, 2015
30.48 M Stocks
Jan 1, 2016
316.30 M Stocks

Proto Script Pharmaceutical stock splits

In Proto Script Pharmaceutical's history, there have been no stock splits.
Price targets and forecasts for Proto Script Pharmaceutical are not yet available.

Proto Script Pharmaceutical Executives and Management Board

MR

Ms. Michelle Rico

(49)

President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director · since 2016

Frequently asked questions about Proto Script Pharmaceutical

The business model of Proto Script Pharmaceutical Corp focuses on developing and commercializing innovative pharmaceutical products. With a strong emphasis on research and development, Proto Script aims to discover and bring to market cutting-edge medicines to improve patient health outcomes. By actively pursuing partnerships and collaborations within the healthcare industry, Proto Script seeks to leverage its expertise and intellectual property portfolio to drive growth and expand its product pipeline. Through its business model, Proto Script Pharmaceutical Corp aims to contribute to the advancement of healthcare by delivering novel therapeutic solutions to address unmet medical needs.

All fundamentals and in-depth analysis of Proto Script Pharmaceutical

Our stock analysis for Proto Script Pharmaceutical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Proto Script Pharmaceutical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Revenue→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Net Income→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical P/E→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical P/S→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical EBIT→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Dividend→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Directors Dealings→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Stocks→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Market capitalization→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Debt→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Liabilities→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Equity→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical AAQS→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Employees→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical ROE→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical ROA→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical ROCE→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical News→
Proto Script Pharmaceutical Stock
Proto Script Pharmaceutical Analyst Price Targets→

— Stocks

Protrade Applied MaterialsProspect Ridge ResourcesProUroCare MedicalProphecy DeFiProvenance GoldPromino Nutritional SciencesProvidence Gold MinesPrologic Management SystemsPrudential Sugar CorpProlife IndustriesPS International GroupProgrex VenturesAll Stocks A–Z →